PROK
ProKidney Corp.
PROK lost money over the past year, so it has no meaningful PE right now.
PROK Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Weak | |
| Weak | |
| Unavailable |
PROK's revenue, profitability and cash flow are currently under pressure. There isn't enough data to rate its balance sheet.
PROK PE Valuation
PROK has no meaningful PE right now: it lost money over the past year.
PROK Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses steady | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect PROK's revenue to grow, with its earnings and profitability holding steady. However, they disagree widely on these estimates.
PROK Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.62 | -$0.07 |
| Q2 2026 | -$0.57 | $0.00 |
| Q1 2026 | -$0.55 | +$0.05 |
| Q4 2025 | -$0.52 | +$0.11 |
| Q3 2025 | -$0.55 | +$0.01 |
| Q2 2025 | -$0.57 | +$0.03 |
| Q1 2025 | -$0.60 | -$0.02 |
PROK lost $0.62 per share over the past year, a bigger loss than the year before.
PROK Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $174K | -20% |
| Q2 2026 | $150K | -32% |
| Q1 2026 | $226K | -1.7% |
| Q4 2025 | $225K | +196% |
PROK's revenue is growing: $174,000 last quarter, down 20% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -30895% | -13136 points |
| Q2 2026 | -32249% | -14281 points |
| Q1 2026 | -19882% | -1887 points |
| Q4 2025 | -20165% | +47692 points |
| Q3 2025 | -17760% | N/A |
| Q2 2025 | -17968% | N/A |
| Q1 2025 | -17995% | N/A |
| Q4 2024 | -67857% | N/A |
PROK's operating margin was −30895% last quarter, down 13135 points from the same quarter a year ago.
PROK Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$39.9M | -$8.1M |
| Q2 2026 | -$44.2M | -$9.7M |
| Q1 2026 | -$45.5M | -$14.7M |
| Q4 2025 | -$38.3M | +$11.4M |
| Q3 2025 | -$31.8M | -$148K |
| Q2 2025 | -$34.5M | +$4.4M |
| Q1 2025 | -$30.7M | +$4.9M |
| Q4 2024 | -$49.7M | -$22.7M |
PROK has burned cash in almost every quarter: −$168M over the past year, against −$147M the year before.
PROK Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +62% | +116M shares |
| 1 year | +124% | +167M shares |
| 3 years | +391% | +241M shares |
PROK has 302M diluted shares, up 124% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2026 | — |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | — |
| Q3 2024 | — |
PROK Net Leverage
PROK's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
PROK Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 38.2 | Neutral |
| Stochastic | 15.2 | Oversold |
PROK's weekly RSI is 38 (neutral) and its Stochastic is 15 (oversold).
PROK PE vs Healthcare Sector
PROK has no meaningful PE right now: it lost money over the past year.
PROK Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.42 | 19% below |
| 20 week MA | $1.60 | 28% below |
| 50 week MA | $1.86 | 38% below |
| 100 week MA | $1.83 | 37% below |
| 200 week MA | $3.48 | 67% below |
PROK is in a downtrend: it's below all five of its weekly moving averages, and 67% below its 200-week average.
PROK Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $10.1 | $9.86 | -1.9% |
| 2022 | $9.86 | $6.53 | -34% |
| 2023 | $6.53 | $1.78 | -73% |
| 2024 | $1.78 | $1.70 | -4.5% |
| 2025 | $1.70 | $2.53 | +49% |
| 2026 YTD | $2.53 | $1.15 | -55% |
PROK has finished lower in four of the last five years. It's down 55% so far in 2026.